• Journal of Radiation Protection and Research
• /
• 제35권2호
• /
• pp.85-90
• /
• 2010

본 연구에서는, 에너지에 따른 peak의 상대효율을 구하였으며, 검출기의 응답함수를 작성하였다. 이를 위해 고효율, 고분해능을 가진 HPGe 검출기(지름 78.7 mm, 길이 86.5 mm)를 이용하였으며 콤프턴 억제용으로 NaI 검출기를 사용하였다. 감마선 스펙트럼은 $^{23}Na$(p, $\gamma$)$^{24}Mg$ 및 $^{27}Al$(p, $\gamma$)$^{28}Si$ 반응을 이용하여 얻었으며, 이 때 입사 입자의 에너지는 각각 $E_p$ = 1424 keV 및 $E_p$ = 992 keV 이었다. 한편 스펙트럼 측정은 입사 빔 방향에 대해 $55^{\circ}$에서 하였으며, 사용한 가속기는 일본 동경공업대학의 3 MeV Pelletron 가속기를 이용하였다. 검출기의 응답함수는 1.2 MeV에서 9.4 MeV까지 0.75 MeV 간격으로 작성하였다.

• Radiation Oncology Journal
• /
• 제27권4호
• /
• pp.240-248
• /
• 2009

목 적: 방사선치료 관련 연구를 수행함에 있어서 선량 체적 히스토그램(dose volume histogram, DVH)을 분석하는 것이 필수적이나 상용 방사선치료계획시스템에서 수행할 수 없다. 본 연구는 이러한 선량 체적 히스토그램의 정보를 쉽게 분석할 수 있도록 소프트웨어를 제작하였다. 대상 및 방법: 방사선치료계획 시스템에서 치료계획 후에 환자의 DVH 데이터를 텍스트로 저장하여 이를 이용해서 DVH 상에서의 필요한 특정 값들(Vx, Dx)을 지정하여 획득할 수 있도록 하였고, Niemierko의 generalized equivalent uniform dose (EUD), Lyman-Kutcher-Burman 모델을 이용한 normal tissue complication probability (NTCP) 및 방사선치료의 2차 암유발 위험도 인자인 organ equivalent dose (OED)를 계산하는 프로그램을 개발하였다. 결 과: 환자의 데이터를 가지고 실제 방사선치료계획 시스템 상에서의 Vx, Dx와 NTCP 비교를 통해 개발된 프로그램의 계산 알고리즘을 검증하였고 0.1% 내의 오차를 보였으며 EUD 및 OED도 성공적으로 계산되었다. 결 론: 선량 체적 히스토그램을 분석하는 프로그램을 개발하였으며 다양한 방사선치료 관련 연구에 활용할 수 있을 것으로 예상된다.

• Journal of Korean Society for Atmospheric Environment
• /
• 제17권E1호
• /
• pp.1-7
• /
• 2001

The elemental characteristics of atmospheric aerosols were investigated as a function of particle size and water solubility. The aerosol particles were samples at 12 individual size ranges between 0.01 and 30㎛. Collected aerosol particles were separated into both soluble and insoluble components. The concentrations of 15 elements in both components were determined by a PIXE analysis using a 2.0 MeV-proton beam. In general, the mass size distribution of particulate matter was represented as a bimodal distribution. The maximum rations of S in July and December were 5.5 and 3.8 %, and they appeared in the size range of 0.47∼1.17㎛(stage No. 6 or 7) . The ratios of a S at non-separated size were 3.1 and 2.2 % in July and December, respectively, On the other hand, the maximum rations of Si in July and December were 7.0 and 5.4% and they appeared in the size range of 5.1∼30㎛(stage No. 0∼2). The ratios of Si at the non-separated size were 2.1 and 1.8% in July and December, respectively, The mass diameter of 12 elements ranged between 0.59㎛ of S and 3.20 of Fe. More than 90% of atmospheric aerosols consisted of the light elements such as C, N, O, H and Al. The soluble component was dominant in the smaller size range and the insoluble component in the larger size range. Large portions of Si. Ti and Fe existed in insoluble state. By contrast, S, Cl, Ca, Zn and Br were dissolved in water.

• 한국의학물리학회:학술대회논문집
• /
• 한국의학물리학회 2002년도 Proceedings
• /
• pp.267-268
• /
• 2002

Microbeam is a new avenue of radiation research especially in radiation biology and radiation protection. Selective irradiation of an ionizing particle to a targeted cell organelle may disclose such mechanisms as signal transaction among cell organelles and cell-to-cell communication in the processes toward an endpoint observed. Bystander effect, existence of which is clearly evidenced by application of the particle microbeam to biological experiments, suggests potential underestimation in the conventional risk estimation at low particle fluence rates, such as environment of space radiations in ISS (International Space Station). To promote these studies we started the construction of our microbeam facility (named as SPICE) to our HVEE Tandem accelerator (3.4 MeV proton and 5.1 MeV $^4$He$\^$2+/). For our primary goal, "irradiation of single particle to cell organelle within a position resolution of 2 micrometer in a reasonable irradiation time", special features are considered. Usage of a triplet Q magnet for focussing the beam to submicron of size is an outstanding feature compared to facilities of other institutes. Followings are other features: precise position control of cell dish holder, design of the cell dish, data acquisition of microscopic image of a cell organelle (cell nucleus) and data processing, a reliable particle detection, soft and hard wares to integrate all these related data, to control and irradiate exactly determined number of particles to a targeted spot.

• 한국방사선학회논문지
• /
• 제1권1호
• /
• pp.45-49
• /
• 2007

동경공업대학교의 3MV 펠레트론가속기를 사용하여 10에서 90keV 영역에 대하여 $^{197}Au$의 중성자포획 스펙트럼을 측정하였다. 중성자 펄스빔은 $^7Li(p,n)^7Be$반응을 통하여 발생되었다. 사용되어진 양성자 빔의 폭은 1.5-ns였다. 금 시료에 입사된 중성자의 에너지 스펙트럼은 $^6Li$-glass 섬광검출기의 중성자 비행시간법을 사용하여 측정하였다. 금 시료의 중성자포획에 의해서 발생된 감마선은 anti-Compton NaI(TI) 검출장비를 사용하여 측정되었다. 본 연구에서는 5개의 중성자 에너지 역영을 선택했고, 각각의 에너지영역에서 얻어진 감마선파고스펙트럼을 표시하였다. 본 연구에서 얻어진 스펙트럼은 처음으로 얻어진 결과이며, 중성자 결합에너지부근에 몇 개의 천이 피크가 보인다.

• Nuclear Engineering and Technology
• /
• 제5권1호
• /
• pp.38-43
• /
• 1973

A $X_4$형분자인 C $H_4$, Si $H_4$, Ge $H_4$, C $F_4$, Si $F_4$ 및 Ge $F_4$의 양자 또는 불소원자핵의 spin과 분자의 회전사이의 상호작용의 크기를 나타내는 spin-rotation constant $c_{av}$ 를 분자선자기공명방법에 의하여 실험적으로 결정하였다. 강자장근사에 의한 Hamiltonian 은 W $m_{I}$ $m_{J}$=- $g_{I}$ $m_{I}$H- $g_{J}$ $m_{J}$H- $C_{av}$ $m_{I}$ $m_{J}$로 주어지며, $c_{av}$ 는 C tensor의 trace의 3분지 1이 된다. 원자핵자기공오곡선은 v=- $g_{I}$H- $c_{av}$ $m_{J}$로 주어지는 여러개의 회전광공오선의 중첩으로 이룩되며, 전체곡선은 Gauss곡선으로 근사하여 $c_{av}$ 값을 구하였다. 회전공오선은 v= $g_{J}$H- $C_{av}$ $m_{I}$로 주어지며, $m_{I}$는 0, $\pm$1, $\pm$2의 값을 갖는다. $c_{av}$ 의 크기는 인접하는 두 회전공오곡선사이의 진동수치로서도 구할수 있다. 본실험에서 원자핵공오과 회전공오 공히 이용되였다. $c_{av}$ 의 부호는 분자선자기공오실험에서 쓰이는 방법으로서, 양자화되여서 불균일자장에서 분리된 분자선을 진행하는 방향의 좌측 또는 우측에서 부분적으로 차단하면서, 공오곡선의 변화를 보는것으로, 결정된 부호 와 $c_{av}$ 의 크기는 다음과 같다. C $H_4$; -10.3$\pm$0.4kHz Si $H_4$; +3.71$\pm$0.08kHz / Ge $H_4$; +3.79$\pm$0.13kHz C $F_4$; -6.81$\pm$0.08kHz / Si $F_4$; -2.46$\pm$0.06kHz Ge $F_4$; -1.84$\pm$0.04kHz

• 한국의학물리학회지:의학물리
• /
• 제28권4호
• /
• pp.226-231
• /
• 2017

The aim is to investigate the spectra responsibilities of QD (Quantum Dot) for the innovation of new dosimetry application for therapeutic Megavoltage X-ray range. The unique electrical and optical properties of QD are expected to make it a good sensing material for dosimeter. This study shows the spectra responsibility of toluene based ZnCd QD and PPO (2.5-diphenyloxazol) mixed liquid scintillator. The QDs of 4 sizes corresponding to an emission wavelength (ZnCdSe/ZnS:$440{\pm}5nm$, ZnCdSeS:470, 500, $570{\pm}5nm$) were utilized. A liquid scintillator for control sample was made of toluene, PPO. The Composition of QD loaded scintillators are about 99 wt% Toluene as solvent, 1 wt% of PPO as primary scintillator and 0.05, 0.1, 0.2 and 0.4 wt% of QDs as solute. For the spectra responsibility of QD scintillation, they were irradiated for 30 second with 6 MV beam from a LINAC ($Infinity^{TM}$, Elekta). With the guidance of 1.0 mm core diameter optical fiber, scintillation spectrums were measured by a compact CCD spectrometer which could measure 200~1,000 nm wavelength range (CCS200, Thorlabs). We measured the spectra responsibilities of QD loaded organic liquid scintillators in two scintillation mechanisms. First was the direct transfer and second was using wave shifter. The emission peaks from the direct transfer were measured to be much smaller luminescent intensity than based on the wavelength shift from the PPO to QDs. The emission peak was shifted from PPO emission wavelength 380 nm to each emission wavelength of loaded QD. In both mechanisms, 500 nm QD loaded samples were observed to radiate in the highest luminescence intensity. We observed the spectra responsibility of QD doped toluene based liquid scintillator in order to innovate QD dosimetry applicator. The liquid scintillator loading 0.2 wt% of 500 nm emission wavelength QD has most superior responsibility at 6 MV photon beam. In this study we observed the spectra responsibilities for therapeutic X-ray range. It would be the first step of innovating new radiation dosimetric methods for radiation treatment.

• Radiation Oncology Journal
• /
• 제34권4호
• /
• pp.265-272
• /
• 2016

Purpose: The purpose of this study is to evaluate the treatment outcomes of adjuvant radiotherapy using vaginal brachytherapy (VB) with a lower dose per fraction and/or external beam radiotherapy (EBRT) following surgery for patients with stage I endometrial carcinoma. Materials and Methods: The subjects were 43 patients with the International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial cancer who underwent adjuvant radiotherapy following surgery between March 2000 and April 2014. Of these, 25 received postoperative VB alone, while 18 received postoperative EBRT to the whole pelvis; 3 of these were treated with EBRT plus VB. The median EBRT dose was 50.0 Gy (45.0-50.4 Gy) and the VB dose was 24 Gy in 6 fractions. Tumor dose was prescribed at a depth of 5 mm from the cylinder surface and delivered twice per week. Results: The median follow-up period for all patients was 57 months (range, 9 to 188 months). Five-year disease-free survival (DFS) and overall survival (OS) for all patients were 92.5% and 95.3%, respectively. Adjuvant radiotherapy was performed according to risk factors and stage IB, grade 3 and lymphovascular invasion were observed more frequently in the EBRT group. Five-year DFS for EBRT and VB alone were 88.1% and 96.0%, respectively (p = 0.42), and 5-year OS for EBRT and VB alone were 94.4% and 96%, respectively (p = 0.38). There was no locoregional recurrence in any patient. Two patients who received EBRT and 1 patient who received VB alone developed distant metastatic disease. Two patients who received EBRT had severe complications, one each of grade 3 gastrointestinal complication and pelvic bone insufficiency fracture. Conclusion: Adjuvant radiotherapy achieved high DFS and OS with acceptable toxicity in stage I endometrial cancer. VB (with a lower dose per fraction) may be a viable option for selected patients with early-stage endometrial cancer following surgery.

• 대한핵의학회지
• /
• 제25권2호
• /
• pp.286-293
• /
• 1991

$^{123}I$, which is applied for the thyroid and other in vivo kinetic study, has a special role in life sciences. The 159 KeV $\gamma-ray$ from $^{123}I$ is almost ideally appropriate for the current imaging instrumentation. Its decay mode (electron capture) and short half-life (13.3 hr) reduced the burden of radiation dose to the patients, and its chemical property makes it easy to synthesize the labelling compounds. In this experiment, the production of $^{123}I$ via the nuclear reaction $^{124}Te(p,2n)^{123}I$ with 28 MeV protons was sutdied. $TeO_2$ is used as a target material, because it has good physical properties. The target was prepared with $TeO_2$ powder and was molten into a ellipsoidal cavity (a=14 mm, b=10 mm, $270.8mg/cm^2$ thick) of pure platinum. The irradiation was carried out in the external proton beam with incident energies range from 28 MeV to 22 MeV, and current was $30{\mu}A$. The loss of $TeO_2$ target was significantly reduced by using $4\pi-cooling$ system in irradiation. The dry distillation method was adopted for the separation of $^{123}I$ from irradiated target, and when it was kept 5 minutes at $780^{\circ}C$, its result was quantitative. The loss of the target material $(TeO_2)$ was below 0.2% for each production run and $^{123}I$ from the dry distillation apparatus was captured with 0.01 N NaOH in $Na^{123}I$ form, then the pH of the solution was adjusted to $7.5\sim9.0$ with HC1/NaOH. The $Na^{123}I$ solution was passed through $0.2{\mu}m$ membrane filter, and sterilized under high pressure and temperature for 30 minutes. The production of $^{123}I$ is acceptable for clinical application based on the quality of USP XXI.

• Radiation Oncology Journal
• /
• 제29권3호
• /
• pp.156-163
• /
• 2011

Purpose: To evaluate long-term local control rate and toxicity in patients treated with external beam radiotherapy (EBRT) for pituitary adenomas. Materials and Methods: We retrospectively reviewed the medical records of 60 patients treated with EBRT for pituitary adenoma at Korea University Medical Center from 1996 and 2006. Thirty-five patients had hormone secreting tumors, 25 patients had non-secreting tumors. Fifty-seven patients had received postoperative radiotherapy (RT), and 3 had received RT alone. Median total dose was 54 Gy (range, 36 to 61.2 Gy). The definition of tumor progression were as follows: evidence of tumor progression on computed tomography or magnetic resonance imaging, worsening of clinical sign requiring additional operation or others, rising serum hormone level against a previously stable or falling value, and failure of controlling serum hormone level so that the hormone level had been far from optimal range until last follow-up. Age, sex, hormone secretion, tumor extension, tumor size, and radiation dose were analyzed for prognostic significance in tumor control. Results: Median follow-up was 5.7 years (range, 2 to 14.4 years). The 10-year actuarial local control rates for non-secreting and secreting adenomas were 96% and 66%, respectively. In univariate analysis, hormone secretion was significant prognostic factor (p = 0.042) and cavernous sinus extension was marginally significant factor (p = 0.054) for adverse local control. All other factors were not significant. In multivariate analysis, hormone secretion and gender were significant. Fifty-three patients had mass-effect symptoms (headache, dizziness, visual disturbance, hypopituitarism, loss of consciousness, and cranial nerve palsy). A total of 17 of 23 patients with headache and 27 of 34 patients with visual impairment were improved. Twenty-seven patients experienced symptoms of endocrine hypersecretion (galactorrhea, amenorrhea, irregular menstruation, decreased libido, gynecomastia, acromegaly, and Cushing's disease). Amenorrhea was abated in 7 of 10 patients, galactorrhea in 8 of 8 patients, acromegaly in 7 of 11 patients, Cushing's disease in 4 of 4 patients. Long-term complication was observed in 4 patients; 3 patients with cerebrovascular accident, 1 patient developed dementia. Of these patients, 3 of 4 received more than 60 Gy of irradiation. Conclusion: EBRT is highly effective in preventing recurrence and reducing mass effect of non-secreting adenoma. Effort to improve tumor control of secreting adenoma is required. Careful long-term follow-up is required when relatively high dose is applied. Modern radiosurgery or proton RT may be options to decrease late complications.